Achilles therapeutics reports fourth quarter and year-end 2023 financial results and recent business highlights

– provided interim phase i/iia update on clonal neoantigen reactive t cells in advanced nsclc and melanoma – – improved velos™ manufacturing process delivering higher cnet doses – – protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2h 2024 – – strong cash position of $131.5 million supports operations through 2025 – london, april 04, 2024 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing ai-powered precision t cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended december 31, 2023, and recent business highlights. “in 2023, we made important progress on the optimization of our velos™ manufacturing process with a significant improvement in cnet doses delivered and are developing our understanding of the relationship between host conditioning and the engraftment of infused cnet.
ACHL Ratings Summary
ACHL Quant Ranking